A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 30 Nov 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 24 Nov 2017 Planned End Date changed from 29 Apr 2020 to 30 Jun 2020.
- 24 Nov 2017 Planned primary completion date changed from 29 Apr 2020 to 30 Jun 2020.
- 24 Nov 2017 Planned initiation date changed from 30 Oct 2017 to 30 Nov 2017.